TherapeuticsMD, Inc.
TXMD
$0.9962
-$0.0138-1.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.87% | 1,132.08% | -46.45% | -24.76% | -99.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.87% | 1,132.08% | -46.45% | -24.76% | -99.27% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 32.87% | 1,132.08% | -46.45% | -24.76% | -99.27% |
| SG&A Expenses | -40.45% | -17.61% | -55.66% | -56.74% | -85.73% |
| Depreciation & Amortization | -84.30% | -26.15% | 40.63% | 392.59% | 106.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.67% | -18.26% | -51.43% | -52.81% | -80.16% |
| Operating Income | 80.63% | 51.55% | 52.31% | 57.18% | -102.78% |
| Income Before Tax | 105.24% | 60.46% | 56.50% | 64.98% | -103.27% |
| Income Tax Expenses | 27.91% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 107.40% | 60.46% | 56.50% | 64.98% | -103.18% |
| Earnings from Discontinued Operations | -79.03% | 97.84% | -- | 105.80% | -97.75% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 128.54% | 81.97% | 54.85% | 79.63% | -101.14% |
| EBIT | 80.63% | 51.55% | 52.31% | 57.18% | -102.78% |
| EBITDA | 85.45% | 53.59% | 57.36% | 61.78% | -102.50% |
| EPS Basic | 127.38% | 83.28% | 59.99% | 82.78% | -100.98% |
| Normalized Basic EPS | 29.88% | 63.37% | 61.86% | 70.41% | -102.35% |
| EPS Diluted | 126.16% | 83.02% | 60.63% | 82.93% | -101.17% |
| Normalized Diluted EPS | 29.88% | 63.37% | 61.86% | 70.41% | -102.68% |
| Average Basic Shares Outstanding | 4.45% | 7.77% | 12.85% | 18.23% | 16.45% |
| Average Diluted Shares Outstanding | 4.45% | 7.77% | 12.85% | 18.23% | 1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |